Cardiovascular diseases (CVDs) are among the leading causes of mortality worldwide, and pharmacogenomics offers promising strategies to optimize their treatment. This book explores the application of pharmacogenomic principles in managing CVDs, including hypertension, heart failure, and dyslipidemia. It covers the genetic factors that influence the efficacy and safety of cardiovascular medications such as beta-blockers, ACE inhibitors, statins, and anticoagulants. Designed for cardiologists, pharmacogenomic researchers, and healthcare professionals, it provides insights into enhancing the precision and effectiveness of cardiovascular disease treatments through genetic understanding.
Matthew Phillips is a leader in pharmacogenomics and cardiovascular disease treatment, specializing in how genetic variations affect the response to cardiovascular drugs. His research includes studying how pharmacogenomics can guide the use of medications like statins, anticoagulants, and antihypertensives. Matthew advocates for personalized cardiovascular care based on pharmacogenomic testing to optimize drug therapy and minimize adverse effects. He educates healthcare providers on applying pharmacogenomic insights to improve cardiovascular treatment outcomes.